From Hypertension to Beyond : Unraveling the Diverse Mechanisms of Olmesartan in Disease Modulation
Thieme. All rights reserved..
Olmesartan, originally known for its antihypertensive properties, exhibits promising potential in addressing inflammation-mediated diseases. As an angiotensin II receptor blocker (ARB), Olmesartan influences pivotal pathways, including reactive oxygen species, cytokines, NF-κB, TNF-α, and MAPK. This suggests a viable opportunity for repurposing the drug in conditions such as ulcerative colitis, neuropathy, nephropathy, and cancer, as supported by multiple preclinical studies. Ongoing clinical trials, particularly in cardiomyopathy and nephropathy, suggest a broader therapeutic scope for Olmesartan. Repurposing efforts would entail comprehensive investigations using disease-specific preclinical models and dedicated clinical studies. The drug's established safety profile, wide availability, and well-understood ARB mechanism of action offer distinct advantages that could facilitate a streamlined repurposing process. In summary, Olmesartan's versatile impact on inflammation-related pathways positions it as a promising candidate for repurposing across various diseases. Ongoing clinical trials and the drug's favorable attributes enhance its appeal for further exploration and potential application in diverse medical contexts.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Drug research - 74(2024), 3 vom: 27. März, Seite 93-101 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rind, Laiba [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8W1IQP3U10 |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/a-2244-3136 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368407403 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368407403 | ||
| 003 | DE-627 | ||
| 005 | 20240304232516.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240214s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/a-2244-3136 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM368407403 | ||
| 035 | |a (NLM)38350635 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rind, Laiba |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a From Hypertension to Beyond |b Unraveling the Diverse Mechanisms of Olmesartan in Disease Modulation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a Olmesartan, originally known for its antihypertensive properties, exhibits promising potential in addressing inflammation-mediated diseases. As an angiotensin II receptor blocker (ARB), Olmesartan influences pivotal pathways, including reactive oxygen species, cytokines, NF-κB, TNF-α, and MAPK. This suggests a viable opportunity for repurposing the drug in conditions such as ulcerative colitis, neuropathy, nephropathy, and cancer, as supported by multiple preclinical studies. Ongoing clinical trials, particularly in cardiomyopathy and nephropathy, suggest a broader therapeutic scope for Olmesartan. Repurposing efforts would entail comprehensive investigations using disease-specific preclinical models and dedicated clinical studies. The drug's established safety profile, wide availability, and well-understood ARB mechanism of action offer distinct advantages that could facilitate a streamlined repurposing process. In summary, Olmesartan's versatile impact on inflammation-related pathways positions it as a promising candidate for repurposing across various diseases. Ongoing clinical trials and the drug's favorable attributes enhance its appeal for further exploration and potential application in diverse medical contexts | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a olmesartan |2 NLM | |
| 650 | 7 | |a 8W1IQP3U10 |2 NLM | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Tetrazoles |2 NLM | |
| 700 | 1 | |a Mahmood, Tarique |e verfasserin |4 aut | |
| 700 | 1 | |a Siddiqui, Mohammed Haris |e verfasserin |4 aut | |
| 700 | 1 | |a Ahsan, Farogh |e verfasserin |4 aut | |
| 700 | 1 | |a Shamim, Arshiya |e verfasserin |4 aut | |
| 700 | 1 | |a Anwar, Aamir |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Rajnish Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug research |d 2013 |g 74(2024), 3 vom: 27. März, Seite 93-101 |w (DE-627)NLM225192764 |x 2194-9387 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2024 |g number:3 |g day:27 |g month:03 |g pages:93-101 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-2244-3136 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2024 |e 3 |b 27 |c 03 |h 93-101 | ||